The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance
新型甲苯胺磺酰胺 EL102 在临床前体外和体内实验中表现出对抗前列腺癌的活性,并可绕过 MDR1 耐药性
期刊:British Journal of Cancer
影响因子:6.4
doi:10.1038/bjc.2013.537
A P Toner, F McLaughlin, F J Giles, F J Sullivan, E O'Connell, L A Carleton, L Breen, G Dunne, A M Gorman, J D Lewis, S A Glynn